Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone ...

President Donald Trump put the biopharma industry on its back foot earlier this month with his executive order on ...

Fresenius Kabi Canada announces that its tocilizumab biosimilar Tyenne® referencing Actemra®** (tocilizumab) is now commercially available in Canada. Tyenne® is the first and only tocilizumab ...

After the launch of Ustekinumab, a biosimilar of Stelara, in the United States and Europe, Biocon Biologics’ biosimilar drug ...

There were also five new drugs referencing the ophthalmology drug Eylea (aflibercept) that gained FDA approval in 2024.

Feldman and Schor explain that the patent dance is a complex process to determine which of a biologic manufacturer’s patents ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous ...

Dr Reddys stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, ...